Omega-3 fatty acids, thrombosis and vascular disease

William Harris

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

The cardioprotective effects of long-chain, marine omega-3 fatty acids (ω3 FA) have been demonstrated in animal and human experimental studies, in epidemiological investigations and in randomized, controlled trials. In Western countries, effective intakes of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) appear to be in the 0.5–1 g/day range. The mechanism behind the ω3 FA effect is not known with certainty, but appears to involve the prevention of fatal arrhythmias associated with myocardial ischemia. The extent to which this may be secondary to ω3 FA-induced reductions in thrombotic tendencies is not known. Although the anti-thrombotic properties of larger quantities (>3 g/day) of ω3 FA have been examined, the impact of <1 g/day has not. Current evidence suggests that at very low intakes (150 mg/day of EPA) ex vivo platelet function may be inhibited, and individuals with higher blood levels of ω3 FA have lower levels of tissue plasminogen activator. On the other hand, supplementation with 800–1600 mg/day of EPA+DHA had no effect on coagulation factors. Although further research is needed, these data imply that hemostatic processes may be beneficially impacted by low intakes of ω3 FA, and CHD risk may thereby be reduced.

Original languageEnglish (US)
Pages (from-to)380-383
Number of pages4
JournalInternational Congress Series
Volume1262
Issue numberC
DOIs
StatePublished - May 1 2004
Externally publishedYes

Fingerprint

Eicosapentaenoic Acid
Omega-3 Fatty Acids
Vascular Diseases
Thrombosis
Docosahexaenoic Acids
Blood Coagulation Factors
Tissue Plasminogen Activator
Hemostatics
Myocardial Ischemia
Cardiac Arrhythmias
Epidemiologic Studies
Blood Platelets
Randomized Controlled Trials
Research

Keywords

  • Cardiovascular disease
  • Docosahexaenoic acid
  • Eicosapentaenoic acid
  • Fish oils
  • Hemostasis
  • Platelet aggregation
  • Thrombosis

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Omega-3 fatty acids, thrombosis and vascular disease. / Harris, William.

In: International Congress Series, Vol. 1262, No. C, 01.05.2004, p. 380-383.

Research output: Contribution to journalArticle

Harris, William. / Omega-3 fatty acids, thrombosis and vascular disease. In: International Congress Series. 2004 ; Vol. 1262, No. C. pp. 380-383.
@article{679cf71498564dd3b22d7ec5925fd5e4,
title = "Omega-3 fatty acids, thrombosis and vascular disease",
abstract = "The cardioprotective effects of long-chain, marine omega-3 fatty acids (ω3 FA) have been demonstrated in animal and human experimental studies, in epidemiological investigations and in randomized, controlled trials. In Western countries, effective intakes of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) appear to be in the 0.5–1 g/day range. The mechanism behind the ω3 FA effect is not known with certainty, but appears to involve the prevention of fatal arrhythmias associated with myocardial ischemia. The extent to which this may be secondary to ω3 FA-induced reductions in thrombotic tendencies is not known. Although the anti-thrombotic properties of larger quantities (>3 g/day) of ω3 FA have been examined, the impact of <1 g/day has not. Current evidence suggests that at very low intakes (150 mg/day of EPA) ex vivo platelet function may be inhibited, and individuals with higher blood levels of ω3 FA have lower levels of tissue plasminogen activator. On the other hand, supplementation with 800–1600 mg/day of EPA+DHA had no effect on coagulation factors. Although further research is needed, these data imply that hemostatic processes may be beneficially impacted by low intakes of ω3 FA, and CHD risk may thereby be reduced.",
keywords = "Cardiovascular disease, Docosahexaenoic acid, Eicosapentaenoic acid, Fish oils, Hemostasis, Platelet aggregation, Thrombosis",
author = "William Harris",
year = "2004",
month = "5",
day = "1",
doi = "10.1016/j.ics.2003.12.097",
language = "English (US)",
volume = "1262",
pages = "380--383",
journal = "International Congress Series",
issn = "0531-5131",
publisher = "Elsevier BV",
number = "C",

}

TY - JOUR

T1 - Omega-3 fatty acids, thrombosis and vascular disease

AU - Harris, William

PY - 2004/5/1

Y1 - 2004/5/1

N2 - The cardioprotective effects of long-chain, marine omega-3 fatty acids (ω3 FA) have been demonstrated in animal and human experimental studies, in epidemiological investigations and in randomized, controlled trials. In Western countries, effective intakes of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) appear to be in the 0.5–1 g/day range. The mechanism behind the ω3 FA effect is not known with certainty, but appears to involve the prevention of fatal arrhythmias associated with myocardial ischemia. The extent to which this may be secondary to ω3 FA-induced reductions in thrombotic tendencies is not known. Although the anti-thrombotic properties of larger quantities (>3 g/day) of ω3 FA have been examined, the impact of <1 g/day has not. Current evidence suggests that at very low intakes (150 mg/day of EPA) ex vivo platelet function may be inhibited, and individuals with higher blood levels of ω3 FA have lower levels of tissue plasminogen activator. On the other hand, supplementation with 800–1600 mg/day of EPA+DHA had no effect on coagulation factors. Although further research is needed, these data imply that hemostatic processes may be beneficially impacted by low intakes of ω3 FA, and CHD risk may thereby be reduced.

AB - The cardioprotective effects of long-chain, marine omega-3 fatty acids (ω3 FA) have been demonstrated in animal and human experimental studies, in epidemiological investigations and in randomized, controlled trials. In Western countries, effective intakes of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) appear to be in the 0.5–1 g/day range. The mechanism behind the ω3 FA effect is not known with certainty, but appears to involve the prevention of fatal arrhythmias associated with myocardial ischemia. The extent to which this may be secondary to ω3 FA-induced reductions in thrombotic tendencies is not known. Although the anti-thrombotic properties of larger quantities (>3 g/day) of ω3 FA have been examined, the impact of <1 g/day has not. Current evidence suggests that at very low intakes (150 mg/day of EPA) ex vivo platelet function may be inhibited, and individuals with higher blood levels of ω3 FA have lower levels of tissue plasminogen activator. On the other hand, supplementation with 800–1600 mg/day of EPA+DHA had no effect on coagulation factors. Although further research is needed, these data imply that hemostatic processes may be beneficially impacted by low intakes of ω3 FA, and CHD risk may thereby be reduced.

KW - Cardiovascular disease

KW - Docosahexaenoic acid

KW - Eicosapentaenoic acid

KW - Fish oils

KW - Hemostasis

KW - Platelet aggregation

KW - Thrombosis

UR - http://www.scopus.com/inward/record.url?scp=33746513774&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746513774&partnerID=8YFLogxK

U2 - 10.1016/j.ics.2003.12.097

DO - 10.1016/j.ics.2003.12.097

M3 - Article

VL - 1262

SP - 380

EP - 383

JO - International Congress Series

JF - International Congress Series

SN - 0531-5131

IS - C

ER -